NeurOptics
NeurOptics develops and markets innovative technology for use in critical care medicine, neurology, neurosurgery, emergency medicine, ophthalmology, and research. The company is dedicated to improving patient outcomes through advanced pupillometry solutions, including the NPi® Pupillometer systems, which provide accurate and objective measurements of pupil size and reactivity. NeurOptics is recognized as a leader in the science of pupillometry, with its products adopted in over 700 hospitals worldwide and included in more than 130 clinical studies. The company emphasizes ongoing professional development and training for its employees to ensure they are well-prepared to represent its products effectively.
NeurOptics
9223 Research Drive, Irvine, CA 92618 U.S.A.
What We Do
An overview of the clinical applications and benefits of pupillometry in critical care and emergency settings.
A single-patient-use device that facilitates patient data upload into EMR systems, ensuring compliance with HIPAA guidelines.
Integration of pupillometer data into electronic medical records to streamline patient care and documentation.
A handheld device that provides accurate, reliable, and objective pupil size and reactivity data, independent of examiner.
An automated system for measuring pupil reactivity and size, designed for critical care settings.
A portable device that accurately measures pupil size under various light conditions, ideal for refractive surgery.
A research tool used to measure pupil size and reactivity, suitable for clinical studies and trials.
A hand-held device designed for quick and accurate measurement of pupil size and pupillary light reflex.
Diagnostics
Psychological and Cognitive Health and Performance
Key People
Kamran Siminou
Executive Chairman – Founder
William Worthen
President and Chief Executive Officer
Robert Mellen
Venture Partner – Aphelion Capital
News & Updates
NeurOptics announces the 2025 introduction of NPi-Connect at the 2024 American Association of Critical Care Nurses National Teaching Institute & Critical Care Exposition.
Quantitative Pupillometry is featured in the joint American Heart Association and Neurocritical Care Society comprehensive statement on managing patients after cardiac arrest.
A multicenter study indicates that measuring the Neurological Pupil index (NPi) is prognostic of 6-month outcome in acute brain injury patients.
A study published in The Lancet Neurology found that abnormal NPi was strongly associated with long-term mortality and poor neurological outcomes after acute brain injury.
NeurOptics holds multiple patents related to pupillometry technology, including Patent No. 7,967,442 and others.